Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Metastatic Renal Cell Cancer

Known as: kidney cancer, metastatic, renal cell carcinoma, metastatic, Metastatic Renal Cell Carcinoma 
A renal cell cancer that has invaded the renal capsule and has spread to lymph nodes and other anatomic sites. Metastatic renal cell cancer is stage… Expand
National Institutes of Health

Related topics

Related topics

16 relations
Epithelial CellsEpitheliumFlank PainHematuria
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
BACKGROUND In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in… Expand
Is this relevant?
Review
2019
Review
2019
Towards individualized therapy for metastatic renal cell carcinoma
Over the past decade, the treatment landscape for patients with metastatic renal cell carcinoma (RCC) has evolved dramatically… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Background Hypertension (HTN) is an on-target effect of the vascular endothelial growth factor pathway inhibitor, sunitinib. We… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
PURPOSE A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
PURPOSE There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
PURPOSE A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
BACKGROUND Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic approach in renal cell carcinoma… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
The inhibitory receptor CTLA4 has a key role in peripheral tolerance of T cells for both normal and tumor-associated antigens… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
PURPOSE This three-arm randomized study compares response rates and overall survival of patients with metastatic renal cell… Expand
Is this relevant?
Highly Cited
1994
Highly Cited
1994
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
OBJECTIVE To determine the efficacy of treatment using high-dose bolus interleukin 2 (IL-2) in patients with metastatic melanoma… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE